Abstracts tagged "Disease Activity"

Abstract Number: 1430 • ACR Convergence 2022
Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis
Cristiano Moura¹, Luck Lukusa¹, Laura Yan¹, Walter P Maksymowych², Denis Choquette³, Gilles Boire⁴ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: The first biosimilar etanercept (ETA-B) was approved in Canada in 2016, but real-world data comparing the effectiveness of ETA-B versus its equivalent originator (ETA-O)…
Abstract Number: 1609 • ACR Convergence 2022
Comorbidity Clusters in Ankylosing Spondylitis and Their Association with Disease Activity and Functional Impairment: Data from the PSOAS Cohort
Paras Karmacharya¹, Cynthia Crowson², Ryan Lennon³, Dilli Poudel⁴, John Davis³, Alexis Ogdie⁵, Jean Liew⁶, Michael Ward⁷, Mariko Ishimori⁸, Michael Weisman⁹, Matthew Brown¹⁰, Mohammad Rahbar¹¹, Mark Hwang¹², John Reveille¹³ and Lianne Gensler¹⁴, ¹Vanderbilt University, Nashville, TN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic, Rochester, MN, ⁴Indiana Regional Medical Center, Indiana, PA, ⁵Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁶Boston University, Boston, MA, ⁷National Institutes of Health, Rockville, MD, ⁸Cedars-Sinai Health System, Los Angeles, CA, ⁹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹⁰Genomics England, London, United Kingdom, ¹¹University of Texas Health Science Center at Houston, Houston, TX, ¹²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ¹³University of Texas McGovern Medical School, Houston, TX, ¹⁴Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Comorbidities occur more frequently in patients with ankylosing spondylitis (AS) than in the general population and are associated with higher morbidity and mortality. Some…
Abstract Number: 2031 • ACR Convergence 2022
Efficacy and Safety of Telitacicept in Primary Sjögren’s Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial
Dong Xu¹, Shangzhu Zhang¹, Cibo Huang², Chenghui Huang³, Li Qin⁴, Xiaomei Li⁵, Meiqing Chen⁶, Xiumei Liu⁷, Yi Liu⁸, Zhijun Li⁹, Jiankang Hu¹⁰, Chunde Bao¹¹, wei Wei¹², Jing Tian¹³, Xinwang Duan¹⁴, Jianmin Fang¹⁵ and Xiaofeng Zeng¹⁶, ¹Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Beijing Hospital, Beijing, China, ³The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, ⁴Huzhou Third Municipal Hospital, Huzhou, China, ⁵Anhui Provincial Hospital, Hefei, China, ⁶The First Affiliated Hospital of Xiamen University, Xiamen, China, ⁷The First Hospital of Shanxi Medical University, Taiyuan, China, ⁸West China Hospital of Sichuan University, Chengdu, China, ⁹The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ¹⁰Jiangxi Pingxiang People’s Hospital, Shanghai, China, ¹¹Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, ¹²Tianjin Medical University General Hospital, Tianjin, China, ¹³Second Xiangya Hospital of Central South University, Changsha, China, ¹⁴The Second Affiliated Hospital of Nanchang University, Nanchang, China, ¹⁵Shanghai Tongji Hospital, Shanghai, China, ¹⁶Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: To evaluate the efficacy and safety of telitacicept in adult patients with primary Sjögren’s syndrome (pSS) in a phase II randomized double-blind placebo-controlled trial.Methods:…
Abstract Number: 2212 • ACR Convergence 2022
Long-term Efficacy and Safety of Subcutaneous Tocilizumab in Patients with Polyarticular or Systemic Juvenile Idiopathic Arthritis – an Extension Study of 2 Phase 1b Clinical Trials
Hermine Brunner¹, Athimalaipet Ramanan², Gerd Horneff³, Kirsten Minden⁴, Inmaculada Calvo Penades⁵, Mauro Zucchetto⁶, Laura Brockwell⁷, Oliver Gordon⁷ and Fabrizio De Benedetti⁸, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, ²Bristol Royal Hospital for Children, Bristol, United Kingdom, ³Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Pediatric Rheumatology Unit, Hospital Universitario y Politécnico La Fe, València, Spain, ⁶Parexel International, Milano, Italy, ⁷Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁸Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy
Background/Purpose: Dosing regimens for subcutaneous tocilizumab (SC-TCZ) in patients with polyarticular-course or systemic juvenile idiopathic arthritis (pJIA or sJIA) were determined for SC-TCZ in 2…
Abstract Number: 0285 • ACR Convergence 2022
Characteristics and Outcomes of Patients with Rheumatoid Arthritis Treated with Upadacitinib in a Global Real-World Setting
Roberto Felice Caporali¹, Jayeshkumar Patel², Oliver Howell³, sander strengholt⁴, Hannah Jones³ and Peter Taylor⁵, ¹University of Milan, Milano, Italy, ²AbbVie, Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom, ⁴AbbVie, Inc., Abcoude, Netherlands, ⁵University of Oxford, Oxford, United Kingdom
Background/Purpose: Upadacitinib (UPA), a Janus kinase inhibitor, is a newly approved advanced therapy for patients (pts) with rheumatoid arthritis (RA), thus real-world evidence is lacking.…
Abstract Number: 0532 • ACR Convergence 2022
Women with Early Rheumatoid Arthritis Less Likely to Achieve Rapid and Sustainable Remission: Results from the Canadian Early Arthritis Cohort Study
orit schieir¹, Susan Bartlett², Marie-France Valois¹, Glen Hazlewood³, Louis Bessette⁴, Gilles Boire⁵, Carol Hitchon⁶, Edward Keystone⁷, Janet Pope⁸, diane tin⁹, Carter Thorne¹⁰, Vivian Bykerk¹¹ and Canadian Early Arthritis Cohort (CATCH) Investigators¹², ¹McGill University, Montréal, QC, Canada, ²McGill University, Montreal, QC, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹Centre of Arthritis Excellence (CArE), Newmarket, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²The Canadian Early Arthritis Cohort (CATCH), Bowmanville, ON, Canada
Background/Purpose: Historical and established RA cohorts have reported sex disparities in remission outcomes favoring male patients. The objective of the present study was to compare…
Abstract Number: 0905 • ACR Convergence 2022
Predicting Disease Activity in Rheumatoid Arthritis Patients Using Machine Learning: Data from the ACR’s RISE Registry
Eren-Ajani Tshimanga¹, Milena Gianfrancesco², Stefanos Giampanis³, Jing Li², Emma Kersey⁴, Jinoos Yazdany⁵, Beau Norgeot⁶, Gabriela Schmajuk⁷ and Zara Izadi⁴, ¹University of California, Berkeley, Berkeley, CA, ²University of California, San Francisco, San Francisco, CA, ³Anthem, San Francisco, ⁴University of California San Francisco, San Francisco, CA, ⁵UCSF, San Francisco, CA, ⁶Anthem, Oakland, CA, ⁷UCSF / SFVA, San Francisco, CA
Background/Purpose: Predicting the trajectory of disease in individuals with RA is difficult, with numerous factors influencing whether a patient may experience higher or lower disease…
Abstract Number: 1337 • ACR Convergence 2022
Dietary Mineral Intake of an Inner-City Population and Its Impact on Disease Activity in Patients with SLE
Paolo Pio Tempongko, Eugenio Capitle, Steven Keller and Reena Khianey, Rutgers University - New Jersey Medical School, Newark, NJ
Background/Purpose: Many patients implement a complementary dietary approach in addition to conventional pharmacologic therapy for systemic lupus erythematosus (SLE). There is growing evidence that several…
Abstract Number: 1448 • ACR Convergence 2022
Utility of Digital Signals and Patient Reported Data Gathered in a Decentralized Study to Predict SLE Patient-Reported Flares
Eldon Jupe¹, Gerald Lushington², Mohan Purushothaman¹, Fabricio Pautasso¹, Georg Armstrong¹, Arif Sorathia¹, Jessica Crawley¹, Vijay Nadipelli³, Bernie Rubin⁴, Ryan Newhardt¹, Melissa Munroe¹ and Brett Adelman¹, ¹Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OR, ³GlaxoSmithKline, Philadelphia, PA, ⁴GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by varied immune dysregulation. SLE patients often experience episodic flares, leading to organ damage…
Abstract Number: 1610 • ACR Convergence 2022
Are Serological Protease-mediated Peptides of Tissue Remodeling and Inflammation the New Disease Activity Biomarkers in Psoriatic Arthritis Patients?
Solveig S. Groen¹, Signe Holm Nielsen², Anne-Christine Bay-Jensen², Mozhgan Rasti³, Darshini Ganatra³, Katerina Oikonomopoulou³ and Vinod Chandran⁴, ¹Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, ⁴Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Inflammatory and degenerative processes in the joint tissues are hallmarks of patients with psoriatic arthritis (PsA). Here, proteases play a major role in remodeling…
Abstract Number: 2032 • ACR Convergence 2022
Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome
Kunal Chandwar¹, Juhi Dixit¹, Kriti Kishor¹, DOGGA PRASANNA KUMAR², DIGVIJAY EKBOTE³, PUNEET KUMAR¹ and Urmila Dhakad¹, ¹King George's Medical University, Lucknow, India, ²KGMU, LUCKNOW, Uttar Pradesh, India, ³KING GEORGE MEDICAL UNIVERSITY, LUCKNOW, Uttar Pradesh, India
Background/Purpose: To assess major salivary gland involvement by ultrasonography and elastography in patients with Sjögren's syndrome , compare it with controls and correlate the severity…
Abstract Number: 2228 • ACR Convergence 2022
Development of the Takayasu’s Arteritis Integrated Disease Activity Index
Chiara Marvisi¹, Ertugrul Cagri Bolek², Mark Ahlman³, Hugh Alessi⁴, Christopher Redmond⁵, Peter Merkel⁶, Carlo Salvarani⁷, Kaitlin Quinn⁸ and Peter Grayson⁹, ¹Università di Modena e Reggio Emilia and National Institute of Arthritis & Musculoskeletal & Skin Diseases, National Institutes of Health, Bethesda, MD, ²Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham MD, MD, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Reggio Emilia, Italy, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ⁹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Disease activity indices that accurately assess inflammation in Takayasu's arteritis (TAK) are needed. While clinical assessment is often considered the gold standard, determining if…
Abstract Number: 0306 • ACR Convergence 2022
Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Gabriela Schmajuk¹, Nevin Hammam², Jing Li³, David Collier⁴, Greg Kricorian⁵ and Scott Stryker⁶, ¹UCSF / SFVA, San Francisco, CA, ²Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Amgen Inc., Simi Valley, CA, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Amgen Inc., San Francisco, CA
Background/Purpose: Data regarding the maintenance of disease activity (DA) and treatment persistence in patients (pts) who switched from combination therapy to monotherapy for the management…
Abstract Number: 0541 • ACR Convergence 2022
Prevalence of Venous Thrombo-Embolism in Lupus Nephritis and Associated Risk Factors
Tara Tofighi, Jiandong Su and Zahi Touma, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with SLE have an increased risk of developing venous thrombo-embolism (VTE) based on several cohort studies, accounting for significant morbidity and mortality. Lupus…
Abstract Number: 0916 • ACR Convergence 2022
Should RA Patients with Controlled Disease Taper Methotrexate from Targeted Therapy or Continue It? Risk Differences in Sustaining Remission from a Systematic Review and Meta-analysis
Charis Meng, Diviya Rajesh, Bridget Jivanelli, Deanna Jannat-Khah, DrPH, MSPH and Vivian Bykerk, Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with RA often struggle with side effects of methotrexate (MTX). ACR guidelines conditionally recommend the tapering of MTX before tapering biologic (b)DMARDs, but…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].